Nuo Therapeutics Depreciation & Amortization Growth & History (AURX)
Nuo Therapeutics's depreciation and amortization was $85,463 for fiscal 2025.
View full Nuo Therapeutics company overviewNuo Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $85,463 | $62,441 | +271.22% |
| 2024 | 2024-12-31 | $23,022 | $7,695 | +50.21% |
| 2023 | 2023-12-31 | $15,327 | $8,500 | +124.51% |
| 2022 | 2022-12-31 | $6,827 | $6,827 | — |
| 2021 | 2021-12-31 | $0 | $0 | — |
| 2020 | 2020-12-31 | $0 | −$89,859 | — |
| 2019 | 2019-12-31 | $89,859 | −$12,339 | −12.07% |
| 2018 | 2018-12-31 | $102,198 | −$1.0M | −90.82% |
| 2017 | 2017-12-31 | $1.1M | $277,665 | +33.21% |
| 2016 | 2016-12-31 | $836,192 | $95,219 | +12.85% |
| 2015 | 2015-12-31 | $740,973 | $127,473 | +20.78% |
| 2014 | 2014-12-31 | $613,500 | −$478,643 | −43.83% |
| 2013 | 2013-12-31 | $1.1M | −$87,017 | −7.38% |
| 2012 | 2012-12-31 | $1.2M | $547,979 | +86.82% |
| 2011 | 2011-12-31 | $631,181 | $191,003 | +43.39% |
| 2010 | 2010-12-31 | $440,178 | — | — |
Nuo Therapeutics quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $26,198 | $3,142 | +13.63% |
| Q1 2026 | 2026-03-31 | $22,256 | $6,909 | +45.02% |
| Q4 2025 | 2025-12-31 | $42,410 | $14,029 | +49.43% |
| Q3 2025 | 2025-09-30 | $23,148 | $19,176 | +482.78% |
| Q2 2025 | 2025-06-30 | $23,056 | $19,289 | +512.05% |
| Q1 2025 | 2025-03-31 | $15,347 | $11,580 | +307.41% |
| Q4 2024 | 2024-12-31 | $28,381 | — | — |
| Q3 2024 | 2024-09-30 | $3,972 | $300 | +8.17% |
| Q2 2024 | 2024-06-30 | $3,767 | −$20 | −0.53% |
| Q1 2024 | 2024-03-31 | $3,767 | −$334 | −8.14% |
| Q3 2023 | 2023-09-30 | $3,672 | $969 | +35.85% |
| Q2 2023 | 2023-06-30 | $3,787 | $2,431 | +179.28% |
| Q1 2023 | 2023-03-31 | $4,101 | $4,101 | — |
| Q3 2022 | 2022-09-30 | $2,703 | $2,703 | — |
| Q2 2022 | 2022-06-30 | $1,356 | $1,356 | — |
| Q1 2022 | 2022-03-31 | $0 | $0 | — |
| Q3 2021 | 2021-09-30 | $0 | — | — |
| Q2 2021 | 2021-06-30 | $0 | — | — |
| Q1 2021 | 2021-03-31 | $0 | — | — |
| Q3 2019 | 2019-09-30 | $23,882 | −$1,118 | −4.47% |
| Q2 2019 | 2019-06-30 | $26,279 | $279 | +1.07% |
| Q1 2019 | 2019-03-31 | $25,205 | −$879 | −3.37% |
| Q3 2018 | 2018-09-30 | $25,000 | −$26,000 | −50.98% |
| Q2 2018 | 2018-06-30 | $26,000 | −$55,000 | −67.90% |
| Q1 2018 | 2018-03-31 | $26,084 | −$283,961 | −91.59% |
| Q3 2017 | 2017-09-30 | $51,000 | — | — |
| Q2 2017 | 2017-06-30 | $81,000 | — | — |
| Q1 2017 | 2017-03-31 | $310,045 | $101,482 | +48.66% |
| Q1 2016 | 2016-03-31 | $208,563 | $39,570 | +23.42% |
| Q3 2015 | 2015-09-30 | $186,992 | $144,448 | +339.53% |
| Q2 2015 | 2015-06-30 | $176,729 | −$44,168 | −19.99% |
| Q1 2015 | 2015-03-31 | $168,993 | −$48,680 | −22.36% |
| Q3 2014 | 2014-09-30 | $42,544 | −$211,736 | −83.27% |
| Q2 2014 | 2014-06-30 | $220,897 | −$66,960 | −23.26% |
| Q1 2014 | 2014-03-31 | $217,673 | −$115,274 | −34.62% |
| Q3 2013 | 2013-09-30 | $254,280 | −$67,632 | −21.01% |
| Q2 2013 | 2013-06-30 | $287,857 | −$6,727 | −2.28% |
| Q1 2013 | 2013-03-31 | $332,947 | $108,276 | +48.19% |
| Q3 2012 | 2012-09-30 | $321,912 | $165,312 | +105.56% |
| Q2 2012 | 2012-06-30 | $294,584 | $135,254 | +84.89% |
| Q1 2012 | 2012-03-31 | $224,671 | $65,090 | +40.79% |
| Q3 2011 | 2011-09-30 | $156,600 | $6,919 | +4.62% |
| Q2 2011 | 2011-06-30 | $159,330 | — | — |
| Q1 2011 | 2011-03-31 | $159,581 | — | — |
| Q3 2010 | 2010-09-30 | $149,681 | — | — |
Nuo Therapeutics depreciation and amortization trends
Over the last five fiscal years, Nuo Therapeutics's depreciation and amortization increased from $0 to $85,463, a change of $85,463. The latest reported quarter, Q2 2026, shows $26,198.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nuo Therapeutics source filings ↗